EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Stoke Therapeutics's Enterprise Value is €116.14 Mil.
Stoke Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-80.65 Mil. Therefore, Stoke Therapeutics's EV-to-FCF for today is -1.44.
The historical rank and industry rank for Stoke Therapeutics's EV-to-FCF or its related term are showing as below:
STU:0GT'
s EV-to-FCF Range Over the Past 10 Years
Min: -34.9 Med: -4.21 Max: 0.75
Current: -1.64
During the past 8 years, the highest EV-to-FCF of Stoke Therapeutics was 0.75. The lowest was -34.90. And the median was -4.21.
STU:0GT's EV-to-FCF is ranked worse than 100% of 440
companies
in the Biotechnology industry
Industry Median: 2.895
vs STU:0GT: -1.64
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Stoke Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Stoke Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Stoke Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's EV-to-FCF falls into.
Stoke Therapeutics's current Enterprise Value is €116.14 Mil.
Stoke Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-80.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stoke Therapeutics's PE Ratio (TTM) for today is calculated as:
Stoke Therapeutics's share price for today is €5.55.
Stoke Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.546.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Stoke Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Stoke Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:0GT has been successfully added to your 